Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry
Polina Pyatilova(Humboldt-Universität zu Berlin), Pavel Kolkhir(Fraunhofer Institute for Translational Medicine and Pharmacology), Jonny Peter(University of Cape Town), Riccardo Asero(Ospedale San Carlo), Joachim Dissemond(Essen University Hospital), Pascale Salameh(Lebanese University), Stamatios Gregoriou(Andreas Sygros Hospital), Μichael Μakris(National and Kapodistrian University of Athens), Maryam Khoshkhui(Mashhad University of Medical Sciences), Kanokvalai Kulthanan(Siriraj Hospital), Mojca Bizjak(University Clinic of Pulmonary and Allergic Diseases Golnik), Papapit Tuchinda(Siriraj Hospital), Cascia Day(University of Cape Town), Agnieszka Sikora(Medical University of Silesia), Andrea Bauer(University Hospital Carl Gustav Carus), A. Du‐Thanh(Centre Hospitalier Universitaire de Montpellier), Petra Staubach(Johannes Gutenberg University Mainz), Frank Siebenhaar(Humboldt-Universität zu Berlin), David Pesqué(Universitat Pompeu Fabra), Olga A. Мukhina(City Clinical Hospital), Mateusz Zamłyński(Medical University of Silesia), Elena Kovalkova(Moscow Research and Clinical Center for Neuropsychiatry), Daria Fomina(Sechenov University), Tomasz Hawro(Unknown), Yana Hackler(Humboldt-Universität zu Berlin), Emek Kocatürk(Bahçeşehir University), Karsten Weller(Humboldt-Universität zu Berlin), Elizaveta V. Kuznetsova(City Clinical Hospital), Marcus Maurer(Humboldt-Universität zu Berlin), Felix Aulenbacher(Humboldt-Universität zu Berlin), Alicja Kasperska−Zając(Medical University of Silesia), Ana M. Giménez‐Arnau(Universitat Autònoma de Barcelona), Clive Grattan(Guy's Hospital)
Cited by 16
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k